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Abstract: Current guidelines recommend that inotropes should not be used in patients with normal
systolic blood pressure (SBP). However, this is not supported with concrete evidence. We aimed to
evaluate the effect of inotropes in acute heart failure (HF) patients from a nationwide HF registry.
A total of 5625 patients from the Korean Acute Heart Failure (KorAHF) registry were analyzed.
The primary outcomes were in-hospital adverse events and 1-month mortality. Among the total
population, 1703 (31.1%) received inotropes during admission. Inotrope users had a higher event rate
than non-users (in-hospital adverse events: 13.3% vs. 1.4%, p < 0.001; 1-month mortality: 5.5% vs.
2.5%, p < 0.001), while inotrope use was an independent predictor for clinical outcomes (in-hospital
adverse events: ORadjusted 5.459, 95% CI 3.622–8.227, p < 0.001; 1-month mortality: HRadjusted 1.839,
95% CI 1.227–2.757, p = 0.003). Subgroup analysis showed that inotrope use was an independent
predictor for detrimental outcomes only in patients with normal initial SBP (≥90 mmHg) (in-hospital
adverse events: ORadjusted 5.931, 95% CI 3.864–9.104, p < 0.001; 1-month mortality: HRadjusted 3.584,
95% CI 1.280–10.037, p = 0.015), and a propensity score-matched population showed consistent results.
Clinicians should be cautious with the usage of inotropes in acute heart failure patients, especially in
those with a normal SBP.
Keywords: acute heart failure; inotrope; initial systolic; blood pressure
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1. Introduction
Acute heart failure (HF), defined as a rapid onset of, or change in, symptoms and signs of HF can
be a life-threatening condition that requires immediate medical attention [1,2]. Acute HF is itself one
of the leading causes of hospitalization and usually leads to hospitalization, which is associated with
substantial mortality and morbidity [3]. Generally, acute HF occurs following a precipitating factor such
as excessive fluid or salt intake, medication non-adherence, myocardial infarction, or arrhythmia, or
concurrent non-cardiac illness (e.g., infection, embolism, thyroid disease, renal failure, etc.) [4]. The overall
goal of treating acute HF is focused on identifying any precipitating factors, relieving symptoms, and
optimizing long-term therapies. However, despite the vast number of trials investigating optimal
treatment for chronic HF, treatment guidelines for acute HF are still not well established.
The majority of acute HF patients are treated with diuretics to optimize volume status and
vasodilators for symptom resolution and congestion relief. Inotropes can be administered in patients
with hypotension or signs and symptoms of peripheral hypo-perfusion. However, previous clinical
trials have failed to show any benefit from inotropes, even in symptom relief [5–7]. Meanwhile, the
2016 European guidelines confirm inotrope use as a level of recommendation of class III (not to be used)
for patients with normal systolic blood pressure (SBP) >90 mmHg, and without cardiogenic shock.
The evidence supporting this recommendation is quite weak, only derived from retrospective studies
or meta-analyses, which has led to a decrease in adherence to guideline-based therapy. Therefore, the
aim of our study was to support the present guideline by evaluating the effect of inotropes in acute HF
patients from a prospective nationwide HF registry. From our acute HF registry, we comprehensively
evaluated the safety of inotrope use during admission and for a follow-up period.
2. Materials and Methods
The KorAHF (Korean Acute Heart Failure) registry is a prospective multicenter cohort study that
was designed to describe patient characteristics, current treatments, and short- and long-term patient
outcomes among Korean patients with acute HF (NCT01389843). A total of 5625 patients were enrolled
from the KorAHF registry between March 2011 and February 2014 at 10 tertiary centers. The rationale
and detailed study design of the KorAHF registry has been presented in previous publications [8].
Briefly, patients with signs or symptoms of HF and either lung congestion, objective findings of
LV systolic dysfunction, or structural heart disease were eligible for the study. Detailed variables
were collected at baseline admission, and events including all-cause mortality, mortality from HF
aggravation, and re-hospitalization for HF aggravation were recorded after discharge. Follow-up data
up to 60 months after discharge were collected from the patients by the attending physician.
The study protocol was approved by the ethics committee at each participating center, and was
conducted according to the principles of the Declaration of Helsinki. All patients provided written
informed consent for participation in the registry.
2.1. Study Endpoints and Definitions
The clinical outcomes included adverse in-hospital outcomes (defined as all-cause mortality
or aggravation of HF during hospitalization) and all-cause mortality at one month after discharge.
In-hospital mortalities and the causes of death were adjudicated by an independent event committee.
The definition of each category is described in the Supplementary method. This adjudication form
was referenced by the adjudication of death of typical 3-phase randomized control trials such as the
RELAX and RELAX-AHF-2 trial [9,10].
The mortality data for patients who were lost to follow-up were collected from the National
Insurance data or National Death Records.
Inotropes included dobutamine, dopamine, norepinephrine, and vasopressin, while inotrope
use was defined as at least one use of an inotropic agent, regardless of the cause. The initial SBP
was defined as the initial blood pressure measured immediately after admission. Left ventricular
J. Clin. Med. 2018, 7, 368 3 of 13
ejection fraction (LVEF) values were obtained by transthoracic echocardiography performed during
the index hospitalization. Quantitative calculation using the modified Simpson’s biplane method was
recommended for LVEF measurement, but visually estimated LVEF was also accepted as valid for HF
categorization. According to the 2016 ESC HF guidelines, heart failure with preserved ejection fraction
(HFpEF) was defined as LVEF ≥ 50% and heart failure with reduced ejection fraction (HFrEF) was
defined as LVEF < 40%. Subjects missing quantitative LVEF data were excluded from the final analysis.
2.2. Statistical Analyses
All variables and outcome analyses were based on inotrope use. Data were presented as numbers
and frequencies for categorical variables and as means ± standard deviation (SD) for continuous
variables. For comparison among groups, the χ2 test (or Fisher’s exact test when any expected count
was <5 for a 2 × 2 table) for categorical variables and unpaired Student’s t-test or one-way analysis of
variance for continuous variables were applied.
To estimate the predictors of inotrope use and to predict the independent effects of inotrope use
on adverse in-hospital outcomes, we used a multivariable logistic regression model using a stepwise
algorithm. Variables found to be statistically significant in the univariate analysis were included
in the multivariable model, excluding variables that were closely related to other clinical variables.
As a result, variables such as sex, age, body mass index, previous hypertension, previous diabetes
mellitus, previous chronic renal failure, previous percutaneous intervention, previous myocardial
infarction, atrial fibrillation, initial SBP, initial New York Heart Association (NYHA) classification,
LVEF value, vasodilator use, renal replacement therapy during admission, and lab tests such as
sodium, hemoglobin, uric acid, C-reactive protein, and natriuretic peptides (B type natriuretic peptide
or N-terminal pro-B type natriuretic peptide) were included in the model. Assumptions of the logistic
regression model (e.g., dichotomous dependent variable, independence in each observation, linear
relationship between continuous independent variables and the logit transformation of the dependent
variable, and multi-collinearity) were tested. The Cox and Snell R Square and Hosmer–Lemeshow
goodness-of-fit test were used to evaluate model calibration.
Given the difference in baseline characteristics between groups, we used two different matching
processes, the propensity score matching (PSM) method and the inverse probability weighted (IPW)
Cox proportional hazards regression model. For the PSM analysis, we performed 1:1 matching for
inotropic users and non-users. A logistic regression model was conducted to generate the propensity
score, which was the probability that a patient received inotropes. The same variables mentioned
in the preceding paragraph were considered as adjusted covariates to calculate for the propensity
score. Then, a greedy matching algorithm was used to match patients on the logit of the propensity
score with a caliper width of 0.5 of the SD of the logit of the propensity score. Baseline clinical
characteristics and laboratory findings were compared within the propensity score matched group.
The statistical significance for propensity-score matched groups was assessed by a paired t-test or
Wilcoxon signed rank test, or extensions thereof for categorical variables with more than two levels.
The success of the propensity score was estimated by assessing the balance of baseline characteristics
after propensity-score matching. The balance of each variable between the two groups was evaluated
by the standardized mean difference. The identical propensity score was also used in for the IPW Cox
proportional hazards regression model to adjust for uneven distribution of baseline characteristics
between the different groups. C-statistics with 95% confidence intervals (CIs) were calculated to
validate the discriminant function of the model.
A two-sided probability value less than 0.05 was considered to estimate statistically significant
differences. Statistical tests were performed using SPSS v22.0 (IMB Corporation, Armonk, NY, USA)
and Stata, version 10 (2007, Stata Corporation, College Station, TX, USA).
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3. Results
A total of 5625 patients from the KorAHF registry were analyzed. Those with isolated right
HF (154 patients, 2.7%) were excluded, leaving 1703 (31.1%) patients who received inotropes during
admission and 3768 (68.6%) patients who did not receive inotropes (Figure 1). Table 1 shows the
baseline characteristics, while ischemic heart disease was the main underlying etiology of acute HF
was ischemic heart disease (Table S1). Patients who received inotropes had a different risk factor
profile (Table 1), and a distinct medication prescription pattern (Table S2). Among inotrope users
44.7% used multiple inotropic agents, and the mean number of inotropic agent was 1.68 ± 0.88 per
patient (Table S3). For the subgroup analysis, patients were divided into those with a low initial SBP
(<90 mmHg) vs. normal initial SBP (≥90 mmHg) and those with HFrEF vs. HFpEF. Use of inotropes
was more frequent in patients with a low initial SBP than in those with a normal initial SBP (68.4%
[197/288] vs. 28.7% [1478/5144], p < 0.001) and in HFrEF patients than in HFpEF patients (50.3%
[929/1848] vs. 33.6% [237/705], p < 0.001). Interestingly, 19.9% (247/1239) of HFpEF patients with a
normal SBP received inotropes.
Table 1. Demographic and laboratory characteristics between inotrope users and inotrope non-users.
Total Population
(n = 5471)
Inotrope Users
(n = 1703)
Inotrope Non-Users
(n = 3768) p Value
Sex (male) 2919 (53.4%) 1024 (60.1%) 1895 (50.3%) <0.001
Age (years old) 68.6 ± 14.4 66.8 ± 14.8 69.4 ± 14.2 <0.001
BMI (kg/m2) 23.3 ± 3.9 22.9 ± 3.8 23.5 ± 3.9 <0.001
LVEF (%) 37.3 ± 15.5 33.0 ± 14.6 39.2 ± 15.5 <0.001
Risk factors
HTN, n (%) 2211 (40.4%) 791 (46.4%) 1420 (37.7%) <0.001
DM, n (%) 3518 (64.3%) 1053 (61.8%) 2465 (65.4%) 0.010
Smoking, % * 17.9/21.1/61.1 20.3/21.8/57.9 16.8/20.7/62.5 0.002
Previous MI, n (%) 909 (16.6%) 308 (18.1%) 601 (16.0%) 0.051
Previous PCI, n (%) 931 (17.0%) 318 (18.7%) 613 (16.3%) 0.030
Previous CABG, n (%) 287 (5.2%) 113 (6.6%) 174 (4.6%) 0.002
COPD, n (%) 602 (11.0%) 199 (11.7%) 403 (10.7%) 0.280
CRF, n (%) 791 (14.5%) 277 (16.3%) 514 (13.6%) 0.011
Previous CVA, n (%) 833 (15.2%) 237 (13.9%) 596 (15.8%) 0.069
Valve disease, n (%) 769 (14.1%) 295 (17.3%) 474 (12.6%) <0.001
Atrial fibrillation, n (%) 1850 (33.8%) 465 (27.3%) 1385 (36.8%) <0.001
Heart failure Etiology
Ischemic heart disease 2096 (38.3%) 768 (45.1%) 1328 (35.2%) <0.001
Valvular heart disease 763 (13.9%) 289 (17.0%) 474 (12.6%) <0.001
Congenital heart disease 50 (0.9%) 17 (1.0%) 33 (0.9%) 0.659
Cardiomyopathy 1163 (21.3%) 374 (22.0%) 789 (20.9%) 0.392
Hypertension 216 (3.9%) 24 (1.4%) 192 (5.1%) <0.001
Myocarditis 75 (1.4%) 44 (2.6%) 31 (0.8%) <0.001
Infiltrative disease † 69 (1.3%) 13 (0.8%) 56 (1.5%) 0.027
Tachycardia related disease # 586 (10.7%) 69 (4.1%) 517 (13.7%) <0.001
Thyroid related disease $ 29 (0.5%) 4 (0.2%) 25 (0.7%) 0.043
Toxic related disease ‡ 58 (1.1%) 19 (1.1%) 39 (1.0%) 0.787
NYHA at admission, (%) ** 15.2/36.6/48.2 11.1/33.0/55.9 17.1/38.2/44.7 <0.001
Initial SBP (mmHg) 131 ± 30 121 ± 30 136 ± 30 <0.001
Initial DBP (mmHg) 79 ± 19 74 ± 18 81 ± 19 <0.001
Initial HR 93 ± 26 93 ± 25 93 ± 26 0.432
Laboratory analysis
WBC (109/L) 8710 ± 3960 9480 ± 4620 8360 ± 3560 <0.001
Hb (g/dL) 12.4 ± 3.0 12.4 ± 2.3 12.4 ± 2.3 0.465
Platelet (109/L) 211 ± 89 204 ± 89 215 ± 88 <0.001
Total cholesterol (mg/dL) 152 ± 43 148 ± 43 154 ± 43 <0.001
Triglyceride (mg/dL) 100 ± 59 98 ± 64 101 ± 57 0.193
HDL (mg/dL) 41 ± 14 39 ± 14 42 ± 14 <0.001
LDL (mg/dL) 107 ± 55 104 ± 56 108 ± 55 0.059
Na (mEq/L) 138 ± 5 137 ± 5 138 ± 4 <0.001
Uric acid (mg/dL) 7.0 ± 2.9 7.4 ± 3.0 6.9 ± 2.8 <0.001
BUN (mg/dL) 26 ± 16 29 ± 19 25 ± 15 <0.001
Creatinine (mg/dL) 1.49 ± 1.49 1.62 ± 1.60 1.43 ± 1.43 <0.001
Glucose (mg/dL) 156 ± 77 166 ± 86 151 ± 73 <0.001
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Table 1. Cont.
Total Population
(n = 5471)
Inotrope Users
(n = 1703)
Inotrope Non-Users
(n = 3768) p Value
CRP (mg/L) 2.36 ± 4.25 3.15 ± 5.33 2.00 ± 3.60 <0.001
BNP (pg/mL) 1341 ± 1304 1571 ± 1454 1243 ± 1223 <0.001
NTproBNP (pg/mL) 9327 ± 10846 11762 ± 12089 8232 ± 10051 <0.001
BMI, body mass index; LVEF, left ventricular ejection fraction; HTN, hypertension; DM, diabetes mellitus; MI,
myocardial infarction; PCI, percutaneous coronary intervention; CABG, coronary artery bypass graft surgery;
COPD, chronic obstructive pulmonary disease; CRF, chronic renal failure; CVA, cerebrovascular accident; SBP,
systolic blood pressure; DBP, diastolic blood pressure; HR, heart rate; WBC, white blood cell; Hb, hemoglobin;
HDL, high density lipoprotein; LDL, low density lipoprotein, Na; sodium; BUN, blood urea nitrogen; CRP,
C-reactive protein; BUN, brain natriuretic peptide; NTproBNP, n-terminal brain natriuretic peptide. * smoking:
current smoker/ex-smoker/never smoked. † Infiltrative heart disease includes amyloidosis and sarcoidosis.
# Tachycardia-related disease mainly includes atrial fibrillation, Atrial tachycardia and ventricular tachycardia.
$ Thyroid-related disease includes hyperthyroidism and hypothyroidism. ‡ Toxins of toxic related disease include
antineoplastic drugs, heavy metals, and alcohol. ** NYHA: grade 2/grade 3/grade 4.
Figure 1. Flowchart of the Korean Acute Heart Failure (KorAHF) registry. Analysis was performed
to evaluate the effect of inotropes in acute heart failure patients. Subgroup analysis was performed
by initial SBP (low initial SBP (<90 mmHg) vs. normal initial SBP (≥90 mmHg)) LV systolic function
(HFrEF (LVEF ≤ 40%) vs. HFpEF (LVEF ≥ 50%)).
3.1. In-Hospital Clinical Events
In-hospital clinical events occurred in 280 (5.1%) of the cases during admission. Patients who
were given inotropes had a higher rate of in-hospital clinical events (227/1703 (13.3%) vs. 53/3768
(1.4%), p < 0.001), which was consistent with the subgroup analysis (Table 2). Cardiac death occupied
the majority of in-hospital clinical events (70.3%), and the most common cause of cardiac death was HF
aggravation (60.4%; Figure S1). In subgroup analysis, cardiac deaths were more common in inotrope
users compared with non-users (76.2% (173/227) vs. 45.3% (24/53), p < 0.001). Importantly, all eight
cases of in-hospital sudden cardiac death, which was defined as death that occurred unexpectedly in
clinically stabilized patients, occurred in inotrope users, composing 4.6% of total cardiac death events.
In contrast, non-cardiovascular deaths were more common in non-users than users (24.5% (13/53) vs.
13.7% (31/227), p = 0.050).
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Table 2. In hospital clinical event rate. HFpEF, heart failure with preserved ejection fraction; HFrEF,
heart failure with reduced ejection fraction.
Total Inotrope Users Inotrope Non-Users p Value
Total population
Primary endpoint 280/5471 (5.1%) 227/1703 (13.3%) 53/3768 (1.4%) <0.001
Mortality 258/5471 (4.7%) 220/1703 (12.9%) 38/3768 (1.0%) <0.001
Cardiac death 197/5471 (3.6%) 173/1703 (10.2%) 24/3768 (0.6%) <0.001
Normal initial SBP (SBP≥ 90 mmHg)
Primary endpoint 225/5144 (4.4%) 176/1478 (11.9%) 49/3666 (1.3%) <0.001
Mortality 203/5144 (3.9%) 169/1478 (11.4%) 34/3666 (0.9%) <0.001
Cardiac death 153/5144 (3.0%) 130/1478 (8.8%) 23/3666 (0.6%) <0.001
Low initial SBP (SBP < 90 mmHg)
Primary endpoint 44/288 (16.3%) 40/197 (20.3%) 4/91 (4.4%) <0.001
Mortality 44/288 (15.3%) 40/197 (20.3%) 4/91 (4.4%) <0.001
Cardiac death 34/288 (11.8%) 33/197 (16.8%) 1/91 (1.1%) <0.001
HFrEF (EF≤ 40%)
Primary endpoint 179/3198 (6.0%) 150/1167 (12.9%) 29/2031 (1.4%) <0.001
Mortality 161/3198 (5.0%) 143/1167 (12.3%) 18/2031 (0.9%) <0.001
Cardiac death 132/3198 (4.1%) 119/1167 (10.2%) 13/2031 (0.6%) <0.001
HFmrEF (40% < EF < 50%)
Primary endpoint 24/750 (3.2%) 18/181 (9.9%) 6/569 (1.1%) <0.001
Mortality 23/750 (3.1%) 18/181 (9.9%) 5/569 (0.9%) <0.001
Cardiac death 16/750 (2.1%) 12/181 (6.6%) 4/569 (0.7%) <0.001
HFpEF (EF≥ 50%)
Primary endpoint 41/1284 (3.2%) 29/266 (10.9%) 12/1018 (1.2%) <0.001
Mortality 39/1284 (3.0%) 29/266 (10.9%) 10/1018 (1.0%) <0.001
Cardiac death 22/1284 (7.1%) 19/266 (7.1%) 3/1018 (0.3%) <0.001
The use of inotropes was an independent predictor of in-hospital clinical events (ORadjusted 5.459,
95% CI 3.622–8.227, p < 0.001), whereas other independent predictors included factors such as old age,
low body mass index, baseline chronic renal failure, HFrEF, high uric acid level, high C-reactive protein,
and renal replacement therapy during admission (Table 3). When divided into subgroups by the initial
SBP, use of inotropes was only a risk factor in patients with an initial SBP≥ 90 mmHg (ORadjusted 5.931,
95% CI 3.864–9.104, p < 0.001). According to the LV systolic function, inotrope use was an independent
risk factor in both HFrEF (ORadjusted 5.699, 95% CI 3.529–9.205, p < 0.001) and HFpEF (ORadjusted 4.374,
95% CI 1.476–12.962, p = 0.008) (Table S4). There were no significant interactions across subgroups by
the initial SBP (p = 0.133) and LV systolic function (p = 0.999).
Table 3. Independent predictors of in-hospital clinical outcomes. BMI, body mass index; LVEF, left
ventricular ejection fraction; CRF, chronic renal failure.
Odds Ratio 95% CI p
Old age (>70 years old) 2.877 1.908–4.340 <0.001
Low BMI (<25 kg/m2) 1.587 1.009–2.498 0.046
Chronic renal failure 2.254 1.331–3.816 0.002
LVEF (≤40%) 1.715 1.111–2.647 0.015
Uric Acid > 7 mg/dL 1.689 1.182–2.413 0.004
CRP > 0.5 mg/dL 2.636 1.689–4.112 <0.001
Renal replacement therapy during admission 10.657 6.763–16.794 <0.001
Inotrope usage 5.459 3.622–8.227 <0.001
3.2. Post-Discharge 1-Month Mortality
At 1 month after discharge, 3.4% (176/5213) of patients expired, among which inotrope users had
a significantly higher rate of post-discharge 1-month mortality (5.5% (81/1483) vs. 2.5% (95/3730),
p < 0.001) (Table 4). The post-discharge medications are presented in Table S5. Inotrope use was
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an independent predictor of post-discharge 1-month mortality with a HRadjusted of 1.839 (95% CI
1.227–2.757, p = 0.003), while old age, hyponatremia, renal replacement therapy during admission, high
uric acid, and high c-reactive protein were the associated independent predictors (Table 5). As shown
in Figure 2, the post-discharge 1-month survival curve also showed that the 1-month mortality after
discharge was significantly different between inotrope users and non-users.
Figure 2. Post-discharge 1-month mortality events by inotrope use. The post-discharge 1-month
survival curve showed that the post-discharge 1-month mortality was significantly different between
inotrope users and non-users.
In the subgroup analysis by the initial SBP and by LV systolic function, inotrope use had a distinct
effect size according to each subgroup. Inotrope use was an independent predictor of post-discharge
1-month mortality in those with a normal initial SBP (HRadjusted 3.584, 95% CI 1.280–10.037, p = 0.015)
and in those with HFpEF (HRadjusted 54.666, 95% CI 3.479–858.978, p = 0.004, Table S6). The survival
curves showed consistent results, as shown in Figure 3. However, no significant interactions were
observed across subgroups by both initial SBP (p = 0.343) and LV systolic function (p = 0.224).
Table 4. Post-discharge 1-month clinical outcomes. SBP, systolic blood pressure; HFpEF, heart failure
with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction.
Total Inotrope Users Inotrope Non-Users p Value
1-month mortality 176/5213 (3.4%) 81/1483 (5.5%) 95/3730 (2.5%) <0.001
Subgroup—by initial SBP
Low Initial SBP 20/244 (8.2%) 14/157 (8.9%) 6/87 (6.9%) 0.582
Normal Initial SBP 156/4941 (3.2%) 67/1309 (5.1%) 89/3632 (2.5%) <0.001
Subgroup—by LV systolic
function
HFrEF 114/3037 (3.8%) 61/1024 (6.0%) 53/2013 (2.6%) <0.001
HRmrEF 17/727 (2.3%) 5/163 (3.1%) 12/564 (2.1%) 0.484
HFpEF 37/1245 (3.0%) 9/237 (3.8%) 28/1008 (2.8%) 0.406
Table 5. Independent predictors of post-discharge 1-month mortality. CRP, C-reactive protein.
Hazard Ratio 95% CI p
Old age (>70 years old) 2.809 1.739–4.539 <0.001
Hyponatremia 1.572 1.048–2.358 0.029
Uric Acid > 7 mg/dL 1.542 1.052–2.260 0.026
High CRP 1.817 1.153–2.863 0.010
Renal replacement therapy during admission 2.653 1.487–4.734 0.001
Inotrope usage 1.891 1.264–2.829 0.002
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Figure 3. Post-discharge 1-month mortality events by inotrope use in subgroup analysis.
The post-discharge 1-month survival curves showed that (A) mortality evens occurred more often
in inotrope users only in patients with a normal initial SBP (≥90 mmHg), and (B) in patients with a
depressed LV systolic function (LVEF ≤ 40%).
3.3. Propensity Score Matched Population
Because of the distinct baseline characteristics among inotrope users and non-users, we performed
two different methods to compensate for the differences: the PSM method and the IPW Cox
proportional hazards regression model. By using the PSM method, 989 pairs of inotrope users and
non-users were matched. Baseline characteristics showed a decreased difference between the two
groups. Among the PSM population, 114 (5.8%) patients presented with an initial SBP < 90 mmHg,
while the proportion of inotrope users was similar to that among patients presenting with normal
initial SBP (51.8% (59/114) vs. 49.9% (930/1864), p = 0.700). When we compared patients using the
PSM method between normal and low SBP, patients with a low initial SBP were younger, had a lower
body mass index, and had lesser cardiovascular risk factors, such as hypertension, diabetes mellitus,
and valvular diseases than patients with a normal initial SBP (Table S7).
The crude rate of in-hospital adverse outcomes (7.9% (78/989) vs. 1.9% (19/989), p < 0.001)
and post-discharge 1-month mortality (4.2% (39/921) vs. 2.6% (25/989), p = 0.045) was significantly
higher in inotrope users (Table 6). The multivariable regression model showed that inotrope use was
a significant predictor of in-hospital adverse events (ORadjusted 3.893, 95% CI 2.289–6.621, p < 0.001),
and in the subgroup analysis, inotrope use was an independent predictor only in those with a normal
initial SBP (ORadjusted 4.113, 95% CI 2.321–10.897, p < 0.001). Moreover, regarding the post-discharge
1-month clinical follow-up, inotrope use was a marginally significant predictor for post-discharge
1-month mortality (HRadjusted 1.618, 95% CI 0.971–2.697, p = 0.065), while in those with a normal initial
SBP, inotrope use was an independent predictor for post-discharge 1-month mortality (HRadjusted
1.768, 95% CI 1.047–2.986, p = 0.033). We also performed an additional PSM analysis, by extreme
strict matching that left 238 pairs in each population (Table S8). When the difference of baseline
characteristics was almost indistinguishable between inotrope users and non-users, despite the small
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sample size, we could find that the trend was identical to the original analysis; adverse events occurred
more commonly inotrope users.
Table 6. Characteristics and outcomes after propensity score matching.
Inotrope Users (n = 989) Inotrope Non-Users (n = 989) StandardizedMean Difference p Value
Sex (male) 566 (57.2%) 583 (58.9%) 3.2% 0.439
Age (years old) 65.6 ± 15.2 67.2 ± 14.5 10.7% 0.014
BMI (kg/m2) 23.1 ± 3.7 23.1 ± 3.7 0.5% 0.732
LVEF (%) 34.3 ± 15.0 32.8 ± 12.9 10.5% 0.020
Risk factors
HTN, n (%) 560 (56.6%) 523 (52.9%) 7.7% 0.095
DM, n (%) 371 (37.5%) 369 (37.3%) 0.4% 0.926
Smoking, % * 18.8/21.8/59.4 20.4/21.1/58.4 2.1% 0.656
Previous MI, n (%) 166 (16.8%) 161 (16.3%) 1.4% 0.762
Previous PCI, n (%) 168 (17.0%) 180 (18.2%) 3.3% 0.479
Previous CABG, n (%) 68 (6.9%) 64 (6.5%) 1.7% 0.719
COPD, n (%) 118 (11.9%) 90 (9.1%) 9.1% 0.048
CRF, n (%) 152 (15.4%) 118 (11.9%) 9.9% 0.031
Initial SBP 126 ± 29 133 ± 30 23.7% <0.001
Initial DBP 76 ± 18 81 ± 20 26.3% <0.001
Initial HR 93 ± 24 94 ± 25 4.1% 0.290
Valve disease, n (%) 160 (16.2%) 150 (15.2%) 2.9% 0.536
Previous CVA, n (%) 135 (13.7%) 145 (14.7%) 3.0% 0.513
Atrial fibrillation, n (%) 269 (27.2%) 251 (25.4%) 4.2% 0.358
Laboratory analysis
WBC (109/L) 9010±4040 8680 ± 3790 8.4% 0.059
Hb (g/dL) 12.4 ± 2.3 12.6 ± 2.3 8.7% 0.036
Platelet (109/L) 209 ± 93 210 ± 80 1.2% 0.976
Na (m Eq/L) 137± 5 137 ± 5 4.0% 0.368
Uric acid (mg/dL) 7.3 ± 2.8 7.1 ± 3.5 6.3% 0.076
Creatinine (mg/dL) 1.54 ± 1.48 1.35 ± 1.16 14.3% 0.001
Glucose (mg/dL) 163 ± 80 156 ± 75 7.7% 0.029
CRP (mg/L) 2.64 ± 4.59 2.26 ± 3.86 9.0% 0.044
Clinical events
In-hospital adverse
outcomes 7.9% (78/989) 1.9% (19/989) NA <0.001
1-month mortality 4.2% (39/921) 2.6% (25/974) NA 0.045
BMI, body mass index; LVEF, left ventricular ejection fraction; HTN, hypertension; DM, diabetes mellitus; MI,
myocardial infarction; PCI, percutaneous coronary intervention; CABG, coronary artery bypass graft surgery; COPD,
chronic obstructive pulmonary disease; CRF, chronic renal failure; CVA, cerebrovascular accident; WBC, white
blood cell; Hb, hemoglobin; Na; sodium; BUN, blood urea nitrogen; CRP, C-reactive protein; BUN, brain natriuretic
peptide; NTproBNP, n-terminal brain natriuretic peptide. * smoking: current smoker/ex-smoker/never smoked.
The IPW Cox proportional hazards regression model also showed that inotrope use was a
significant predictor of in-hospital adverse clinical outcomes (ORadjusted 1.892, 95% CI 1.285–2.767,
p = 0.001) and post-discharge 1-month mortality (HRadjusted 1.870, 95% CI 1.285–2.721, p = 0.001).
The subgroup analysis showed that inotrope use was an independent predictor for in-hospital adverse
clinical outcomes and post-discharge 1-month mortality only in patients with a normal initial SBP
(in-hospital adverse clinical outcome: ORadjusted 2.924, 95% CI 1.157–7.474, p = 0.021; post-discharge
1-month mortality: HRadjusted 1.829, 95% CI 1.227–2.726, p = 0.003). For patients with a low initial
SBP, inotrope use was not a risk factor for adverse outcomes (in-hospital adverse clinical outcome:
ORadjusted 0.575, 95% CI 0.013–25.167, p = 0.730; post-discharge 1-month mortality: HRadjusted 1.714,
95% CI 0.372–7.893, p = 0.489).
4. Discussion
Our study provides an important insight into the use of inotropes in patients admitted for acute
HF. Of the total population, 31.1% (1703 patients) were inotrope users, among which 88.2% (1478
patients) had a normal initial SBP (SBP ≥ 90 mmHg). In-hospital adverse clinical events occurred in
5.1% (280 patients), and during the post-discharge 1-month follow-up period, 3.4% (176 patients) of the
total population expired. Inotrope use was an independent predictor for in-hospital adverse clinical
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events and post-discharge 1-month mortality. Subgroup analysis revealed that inotrope use had a
different effect size according to the initial SBP and LV systolic function, without significant interaction.
4.1. Inotrope Use in Acute HF
Acute HF is a medical condition that requires immediate medical management, and usually, urgent
hospital admission [11]. The management of acute HF includes rapid recognition of the precipitant
cause, initiation of specific treatment, and prompt symptom control. This includes diuretics for patients
with signs of fluid overload and congestion, vasodilators for symptomatic relief, oxygen for hypoxemic
patients, and thromboembolism prophylaxis [1,2]. In particular, patients with cardiogenic shock
(defined as SBP < 90 mmHg) should receive immediate comprehensive assessment. When choosing
pharmacologic agents to restore organ perfusion by increasing cardiac output and blood pressure,
inotropic agents and vasopressors can be considered, along with device therapies such as intra-aortic
balloon pumps [1]. Although loop diuretics are an essential component of therapy for acute HF, the
limited evidence of previous studies give diuretics a class I recommendation, but based on level B or
level C evidence [12]. Furthermore, the Diuretic Optimization Strategies Evaluation trial showed that
high-dose diuretics might be associated with worsening renal function [13]. The lack of demonstrated
benefit for high-dose diuretics may be related to stimulation of the renin–angiotensin–aldosterone and
sympathetic nervous systems [14].
Accordingly, current guidelines recommend that inotropes, which are sympathetic stimulators,
should be reserved for patients with a severe reduction in cardiac output, resulting in compromised
organ perfusion. In particular, inotropic agents are not recommended before other potentially
correctable factors are present. This is because of the concern for increased adverse effects by
sympathetic stimulators, which is supported by previous studies [15,16].
Despite the negative implications of inotrope use from these studies, almost one-third (31.3%) of
our study population received inotropes. Previous studies have also shown similar rates of inotrope
use in HF patients. In the Italian Network on Heart Failure (IN-HF) outcome registry, 20% received
inotropes [17], and in the Acute Heart Failure Global Survey of Standard Treatment (ALARM-HF)
registry, 33% received inotropes [7]. Interestingly, only a small proportion of inotrope users were
presented with low perfusion or cardiogenic shock (12.2%), elucidating the inappropriate use of
inotropes in real-world practice.
4.2. Hazardous Effect of Inotropes in Acute HF Patients
From our study results, we have demonstrated the hazardous effects of inotrope use in acute
HF patients from a nationwide HF registry. Inotrope use was an independent predictor of in-hospital
adverse outcomes and 1-month mortality. Interestingly, in the subgroup analysis, inotrope use was
only an independent predictor in patients with a normal blood pressure, while inotrope use had
a neutral effect in those with systemic hypotension (SBP < 90 mmHg), even after compensating
baseline risk factors and the different medication prescription patterns in each group. Based on the
negative interaction across subgroups, we can assume that the initial SBP was not a dominant factor in
determining the effect of inotropes, that is, a low initial SBP does not warrant a beneficial or neutral
effect by inotropes. On the contrary, we can assume that a certain subgroup of patients within those
with a low initial SBP may benefit from inotrope use. However, according to the LV systolic function,
inotrope use was a significant predictor of in-hospital adverse outcomes in both HFrEF and HFpEF.
Our results are in line with current guidelines about the use of inotropic agents in the
pharmacological treatment of acute HF. Inotropic agents are not recommended unless the patient
has symptomatic hypotension or is hypoperfused, because of concerns about the safety of inotrope
use (Class III, Level of Evidence A) [18]. In our results, inotrope use was hazardous in patients
without initial hypotension. Meanwhile, guidelines note that short-term inotropes can be considered
in patients with hypotension to maintain peripheral organ perfusion and function (Class IIb, Level
of Evidence C) [1]. Because inotrope use showed deleterious effects on outcomes in our study, we
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can assume that inotropes may be used in very selective cases to improve peripheral hypoperfusion.
Despite the main effect of inotropes and vasopressors, which is to increase cardiac contractility and
cardiac output, and to restore blood pressure, previous data have failed to demonstrate the benefit with
these agents [15–17,19]. This may be related to the deleterious effects of catecholamine stimulation
in HF [20]. In contrast, beta-adrenergic blockers have been shown to reduce mortality and morbidity
in symptomatic HF patients by blocking the effect of catecholamines. By counteracting the effect of
catecholamines, beta-blockers have various effects, including reduction in heart rate, improvement
of left ventricular remodeling, increase in LVEF, reduction in end-systolic volume, and maintaining
anti-arrhythmic action [21,22]. However, this does not deny the potential beneficial effects of inotropes
in selected cases. In patients with systemic hypotension and/or signs of hypoperfusion and shock,
inotropes may be a breakthrough method to overcome the imminent unstable condition.
4.3. Study Limitations
There are several limitations to this study. First, because patients with more severe clinical
presentations are more likely to receive inotropes, inotrope use itself may be associated with worse
clinical outcomes. This was observed in the distinct baseline characteristics between inotrope users and
non-users. We performed various statistical methods to overcome the baseline differences; however,
the possibility that confounding factors may have influenced our study results cannot be ruled out.
Second, the exact dose and duration of inotropes were not analyzed because this was not available
in our dataset. Future studies, which might provide a dose-dependent relationship between adverse
effects and inotrope dosage, could support our study result. Third, regarding the nature of our study
(a retrospective analysis of a prospective cohort), our study results are at best hypothesis-generating.
However, because it is practically very difficult to demonstrate our study results in a randomized
clinical trial, we believe that our study results should be taken with values regarding treatment
strategies for acute HF patients in the clinical setting.
5. Conclusions
Inotropes are still widely used, even in acute HF patients presenting with a normal blood pressure.
The infusion of inotropes is strongly associated with in-hospital adverse outcomes and 1-month
follow-up mortalities. We should be cautious of inotrope use in acute HF patients.
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